ABBV News 48.55 Abbvie Inc. Common Stock (ABBV)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbvie Inc. Common Stock (ABBV) 48.55 $ABBV

3 Reasons the Market Is Down on Gilead Sciences
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
After a solid two-year run, Gilead Sciences   has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from  AbbVie and  Merck  around the corner. In the...

Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...

Glaxo Looking into Misconduct Charges - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:35PM CDT
GlaxoSmithKline recently responded to investigations and charges of misconduct in Jordan and Lebanon.

Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...

Roche Meets Sales Estimates in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:00PM CDT
Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.

Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...

If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...

AbbVie Candidate in Pivotal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:32AM CDT
AbbVie's experimental cancer drug veliparib has been moved into a pivotal study.

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences '  freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...

Glaxo's Tanzeum Approved in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 5:33PM CDT
Glaxo gained approval in the U.S. as an adjunct to diet and exercise in adults suffering from type II diabetes.

Is Johnson & Johnson's Dividend Unbeatable?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
Major health-care stocks out of big pharma and medical devices offer great dividends, but few offer the strength and reliability of sector colossus Johnson & Johnson . While it may not boast the highest yield in health care at only 2.7%, the...

Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences '  highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...

Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 11:41AM CDT
Abbott Laboratories reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents.

Application Now Open for Students with Cystic Fibrosis for the 2014 AbbVie CF Scholarship
PR Newswire - Wed Apr 16, 10:00AM CDT
AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the 2014 AbbVie CF Scholarship, which honors young adults with CF as they pursue higher education. Students can apply for the scholarship from now until Monday, June 9, at www.AbbVieCFScholarship.com.

How Much Has Merck Shaken Up the Hepatitis C Race?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 15, 5:30PM CDT
Even the wildest Gilead bulls seemed to acknowledge that the company was not going to grab and hold 100% share of the hepatitis C (HCV) market. Now the question seems to be shifting to just how much share rivals like AbbVie , Merck , ...

Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:30PM CDT
Bristol-Myers is looking to get the once-daily, single tablet fixed-dose combination approved in conjunction with other antiretroviral agents for the treatment of HIV-1 infection.

Repros Completes Enrollment for Androxal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:15PM CDT
Repros Therapeutics announced it has completed enrollment for one of the two head-to-head studies on its secondary hypogonadism candidate, Androxal.

Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 10:30AM CDT
Abbott Laboratories is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014.

AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer
PR Newswire - Tue Apr 15, 7:00AM CDT
AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial will compare patients randomized to receive either the standard chemotherapies of carboplatin and paclitaxel with the addition of veliparib, versus patients receiving carboplatin and paclitaxel with the addition of placebo.

Hard-to-Cure Patients May Benefit from Merck's HCV Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 4:10PM CDT
Merck presented interim data from an ongoing phase II study on MK-5172 and MK-8742.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 5

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

International Isotopes Enhances Growth with New Facilities

Updated Category News Views 139

International Isotopes Expands Its Operational Footprint International Isotopes, Inc. (OTCQB: INIS) has announced a significant expansion of its operational capabilities with a strategic land acquisition and a new facility lease agreement. This initiative is part of a broader strategy aimed at enhancing the Company's footprint in the radiopharmaceuticals sector. Strategic...

Continue Reading
Humana Achieves Top Honors in Customer Experience Again

Updated Category News Views 80

Humana Excels in Customer Experience for Four Straight Years Humana has once again secured the top position in customer experience among health insurers, according to a recent survey conducted by Forrester. This marks the fourth consecutive year that Humana has achieved this prestigious recognition, reaffirming its commitment to delivering exceptional service and care to...

Continue Reading
BrainStorm Cell Therapeutics Presents Insights into ALS Treatment

Updated Category News Views 128

BrainStorm Cell Therapeutics Webinar on ALS Treatments BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a prominent innovator in adult stem cell therapeutics for neurodegenerative diseases, will be hosting an insightful webinar on current developments in treating amyotrophic lateral sclerosis (ALS). This event is designed to provide essential updates and perspectives...

Continue Reading
Celebrating Excellence: The 2024 Employer Branding Awards Unveiled

Updated Category News Views 235

Overview of the Employer Branding Creativity Awards The "2024 Employer Branding Creativity Awards" organized by the Employer Branding Institute, recognized 75 exemplary companies for their innovative contributions to employer branding. Sponsored by Jaguar Land Rover China, this prestigious event not only celebrates creativity but also demonstrates the rising influence of...

Continue Reading
Battery Recycling Market Expected to Hit $77.1 Billion by 2034

Updated Category News Views 210

Battery Recycling Market Overview The battery recycling market is gaining remarkable traction worldwide, projected to soar to $77.1 billion by 2034. This forecast represents a significant growth trajectory from a valuation of $26.9 billion in 2024, indicating a compound annual growth rate (CAGR) of 11.2% from 2025 to 2034. Impact of Government Regulations Government...

Continue Reading